Skip to main content
. 2022 Jul 28;12:12899. doi: 10.1038/s41598-022-17088-0

Figure 2.

Figure 2

EGCG inhibits entry mediated by spike of highly pathogenic CoVs and a pre-emergent bat CoV. (a-b) EGCG pre-treatment reduced entry of SARS-CoV-1, MERS-CoV, SARS-CoV-2 (ancestral, delta or omicron), or WIV1-CoV pseudoparticles into Huh7 or A549-ACE2 cells. Mean values with standard error of the mean from three independent experiments each done in triplicate are plotted. (c) EGCG inhibits VSV-SARS-CoV-2 infection in Huh7, A549-ACE2 B9 and Calu-3 cells. Its antiviral potency is dependent on the multiplicity of infection (MOI). Mean values with standard deviation of three independent experiments each in duplicate are plotted. (d) Representative images are shown. Scale bar: 200 μm.